» Articles » PMID: 37902878

Gray Matter Loss Relates to Dual Task Gait in Lewy Body Disorders and Aging

Abstract

Background: Within the spectrum of Lewy body disorders (LBD), both Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are characterized by gait and balance disturbances, which become more prominent under dual-task (DT) conditions. The brain substrates underlying DT gait variations, however, remain poorly understood in LBD.

Objective: To investigate the relationship between gray matter volume loss and DT gait variations in LBD.

Methods: Seventy-nine participants including cognitively unimpaired PD, PD with mild cognitive impairment, PD with dementia (PDD), or DLB and 20 cognitively unimpaired controls were examined across a multi-site study. PDD and DLB were grouped together for analyses. Differences in gait speed between single and DT conditions were quantified by dual task cost (DTC). Cortical, subcortical, ventricle, and cerebellum brain volumes were obtained using FreeSurfer. Linear regression models were used to examine the relationship between gray matter volumes and DTC.

Results: Smaller amygdala and total cortical volumes, and larger ventricle volumes were associated with a higher DTC across LBD and cognitively unimpaired controls. No statistically significant interaction between group and brain volumes were found. Adding cognitive and motor covariates or white matter hyperintensity volumes separately to the models did not affect brain volume and DTC associations.

Conclusion: Gray matter volume loss is associated with worse DT gait performance compared to single task gait, across cognitively unimpaired controls through and the LBD spectrum. Impairment in DT gait performance may be driven by age-related cortical neurodegeneration.

Citing Articles

Mapping the neural substrate of high dual-task gait cost in older adults across the cognitive spectrum.

Ali P, Dinomais M, Labriffe M, Pieruccini-Faria F, Montero-Odasso M, Bartha R Brain Struct Funct. 2025; 230(1):25.

PMID: 39755775 PMC: 11700055. DOI: 10.1007/s00429-024-02873-6.


Automated brain segmentation and volumetry in dementia diagnostics: a narrative review with emphasis on FreeSurfer.

Khadhraoui E, Nickl-Jockschat T, Henkes H, Behme D, Muller S Front Aging Neurosci. 2024; 16:1459652.

PMID: 39291276 PMC: 11405240. DOI: 10.3389/fnagi.2024.1459652.


Dementia with Lewy bodies and gait neural basis: a cross-sectional study.

Sainsily-Cesarus A, Schmitt E, Landre L, Botzung A, Rauch L, Demuynck C Alzheimers Res Ther. 2024; 16(1):170.

PMID: 39080741 PMC: 11287986. DOI: 10.1186/s13195-024-01539-z.


Cholinergic nucleus degeneration and its association with gait impairment in Parkinson's disease.

Zhang X, Wang M, Lee S, Yue Y, Chen Z, Zhang Y J Neuroeng Rehabil. 2024; 21(1):120.

PMID: 39026279 PMC: 11256459. DOI: 10.1186/s12984-024-01417-7.


Mild Behavioral Impairment in Parkinson's Disease: An Updated Review on the Clinical, Genetic, Neuroanatomical, and Pathophysiological Aspects.

Angelopoulou E, Bougea A, Hatzimanolis A, Stefanis L, Scarmeas N, Papageorgiou S Medicina (Kaunas). 2024; 60(1).

PMID: 38256375 PMC: 10820007. DOI: 10.3390/medicina60010115.

References
1.
Verghese J, Levalley A, Hall C, Katz M, Ambrose A, Lipton R . Epidemiology of gait disorders in community-residing older adults. J Am Geriatr Soc. 2006; 54(2):255-61. PMC: 1403740. DOI: 10.1111/j.1532-5415.2005.00580.x. View

2.
Verghese J, Annweiler C, Ayers E, Barzilai N, Beauchet O, Bennett D . Motoric cognitive risk syndrome: multicountry prevalence and dementia risk. Neurology. 2014; 83(8):718-26. PMC: 4150127. DOI: 10.1212/WNL.0000000000000717. View

3.
Pistacchi M, Gioulis M, Sanson F, De Giovannini E, Filippi G, Rossetto F . Gait analysis and clinical correlations in early Parkinson's disease. Funct Neurol. 2017; 32(1):28-34. PMC: 5505527. DOI: 10.11138/fneur/2017.32.1.028. View

4.
Mirelman A, Bonato P, Camicioli R, Ellis T, Giladi N, Hamilton J . Gait impairments in Parkinson's disease. Lancet Neurol. 2019; 18(7):697-708. DOI: 10.1016/S1474-4422(19)30044-4. View

5.
Galna B, Lord S, Burn D, Rochester L . Progression of gait dysfunction in incident Parkinson's disease: impact of medication and phenotype. Mov Disord. 2014; 30(3):359-67. DOI: 10.1002/mds.26110. View